Sunday 11 October 2026 Export all SNY data to Excel Powerpack

Sanofi

SNY Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024. In the quarter to June 2026, revenue grew 17.4%, EPS fell 90.8%, free cash flow fell 45.1% and total debt rose 8.23%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

40.07 0.16 −0.40%
Market cap
$95.9B
P/E
21.0×
Fwd P/E
—
Dividend yield
6.05%
F-score
7/9
Altman Z
2.50
Beneish M
−2.63
Dividend safety
58/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— 7 — 6
ROE
0.00% 10.94% 0.00% 5.87%
ROA
7.01% 6.16% 6.06% 3.21%
ROIC
6.17% 6.57% 6.12% 6.58%
Return on Tangible Assets
75.08% 61.72% 72.55% 40.46%
Average Days of Receivables
4.53 68.81 3.75 68.60
Free Cash Flow per Share
0.00 7.62 0.00 6.08
Free Cash Flow
— 18,607.12 — 14,542.46
Capital Expenditures
— (7,417.62) — (7,054.14)
Other line items
Cash ROIC
0.00% 16.79% 0.00% 12.82%
Accounts Receivable Turnover
9.30 5.55 105.97 5.69
Accounts Payable Turnover
0.76 1.79 0.62 1.90
Inventory Turnover
0.64 1.36 0.61 1.30
Average Days of Payables
732.11 205.90 630.21 195.73
Days of Inventory on Hand
815.34 285.70 652.28 304.59
Tax Rate
(0.18) (0.17) (0.17) (0.22)
Research and Development Expense of Revenue
18.12% 16.79% 16.43% 16.58%
Selling, General and Administrative Expense of Revenue
19.05% 20.43% 20.39% 20.11%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Interest Coverage
10.91 15.43 15.83 13.21
Operating CF/Net income
0.00 2.94 0.00 4.61
Depreciation/Fixed assets
0.00 1.22 0.00 1.30
Capex/Depreciation
— (0.53) — (0.45)
Revenue per Share
19.20 21.65 22.77 23.80
Operating CF per Share
0.00 10.66 0.00 9.02
Capex per Share
0.00 (3.04) 0.00 (2.95)
Capex to Sales
0.00 0.14 0.00 0.12

Fold the line items

Columns are period end dates